Antihyperlipidemic Effects of Oyster Mushrooms
The primary goal of this study is to evaluate the short-term safety and potential efficacy of oyster mushrooms (Pleurotus ostreatus) for treatment of hyperlipidemia in HIV-infected patients who are taking Kaletra, a protease inhibitor (PI) that is commonly used in highly active antiretroviral therapy (HAART).
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Antihyperlipidemic Effects of Oyster Mushrooms|
|Study Start Date:||June 2004|
|Study Completion Date:||May 2006|
This is a single-arm, open-label, 8-week "proof of concept" pilot study in 20 subjects to determine if there are detectable lipid-lowering effects of oyster mushrooms in patients with HIV and hyperlipidemia who are taking Kaletra (a ritonavir-containing HAART regimen). The study will also assess whether the concurrent administration of oyster mushrooms and such regimens is safe, and investigate the mechanism of action whereby oyster mushrooms may exert their antihyperlipidemic effect.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00069524
|United States, California|
|General Clinical Research Center, San Francisco General Hospital|
|San Francisco, California, United States|
|Principal Investigator:||Donald I Abrams, MD||University of California, San Francisco|